ESET TRIAL STATUS EPILEPTICUS TRIAL
The first 400 patients were used because of the prespecified stopping rule and the trial stopped for futility. Second-line treatments in benzodiazepine-resistant convulsive status epilepticus: An updated network meta-analysis including the ESET Trial - What did change 1. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.ĭata on adverse events were collected through the first 24 hours after enrollment, for the duration of the trial.Īll-Cause mortality data was collected for the first 400 subjects, which is why the numbers in the All-cause mortality section differ from Participant flow. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.Īdminister 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.Īdminister 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. The first 400 patients were used in several parts of analyses since the trial stopped early for futility (prespecified).Īdminister 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. With regard to the nervous system, epigenetic alterations play a role in a diverse set of processes and have been implicated in a variety of disorders. All enrollments went through the same process of consent even if they were reenrolled. It is becoming increasingly clear that epigenetic modifications are critical factors in the regulation of gene expression. This was an EFIC trial so all consents happened after treatment. Why Should I Register and Submit Results?ĮSETT had a total of 478 enrollments.
0 kommentar(er)
